Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GalenicaGLLNY 76 3-1 Month Momentum % is N/A% as of Sep. 06, 2026. GuruFocus rates GLLNY with a GF Score™ of 76/100. The stock has 1 warning sign investors should review. Among 126 Medical Distribution companies, Galenica ranks better than 50% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-06), Galenica's 3-1 Month Momentum % is N/A%.
The industry rank for Galenica's 3-1 Month Momentum % or its related term are showing as below:
GLLNY's 3-1 Month Momentum % is not ranked *
in the Medical Distribution industry.
Industry Median: 1.365 * Ranked among companies with meaningful 3-1 Month Momentum % only.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Galenica 3-1 Month Momentum % Related Terms
GLLNY vs MCK, COR, CAH: 3-1 Month Momentum % Comparison
For the Medical Distribution subindustry, Galenica's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galenica 3-1 Month Momentum % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Galenica's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Galenica's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galenica (GLLNY) has a 3-1 Month Momentum % of N/A% as of Sep. 06, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Galenica and its competitors. According to the industry distribution chart, Galenica ranks #63 out of 126 companies in the Medical Distribution industry, placing it in the top 50%.
Is Galenica's 3-1 Month Momentum % too high?
Galenica's current 3-1 Month Momentum % is N/A%. Based on the distribution chart, Galenica ranks #63 out of 126 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Galenica has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Galenica's 3-1 Month Momentum % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Galenica ranks #63 out of 126 companies for 3-1 Month Momentum %. This puts Galenica in the upper half of its industry. The industry median 3-1 Month Momentum % is 1.37. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Distribution company?
The median 3-1 Month Momentum % among Medical Distribution companies is 1.37, based on 126 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Galenica and its competitors. For the Medical Distribution industry, the median 3-1 Month Momentum % is 1.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galenica's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galenica stock overvalued right now?
Galenica (GLLNY) has a current 3-1 Month Momentum % of N/A%. The current 3-1 Month Momentum % is N/A%. Galenica's overall GF Score™ is 76/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Galenica (GLLNY), the current 3-1 Month Momentum % is N/A% as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galenica Ltd is an integrated healthcare service provider in Switzerland. The business is operated from two segments Products & Care and Logistics & IT. The Products & Care segment comprises the Retail business area with offerings for patients and end customers and the Professionals business area with offerings for business customers and partners in the healthcare sector. The Logistics & IT segment comprises the two sectors Wholesale and Logistics & IT Services. These provide services for all those involved in the healthcare sector - pharmacies, drugstores, doctors, hospitals and care homes, partners, and suppliers. Geographically, it operates in Switzerland and Other Countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLLNY has been successfully added to your 
